Laurus Labs shines on signing agreement with MPP
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Laurus Labs is currently trading at Rs. 493.25, up by 7.80 points or 1.61% from its previous closing of Rs. 485.45 on the BSE.
The scrip opened at Rs. 483.90 and has touched a high and low of Rs. 493.90 and Rs. 478.40 respectively. So far 73603 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 723.55 on 12-Aug-2021 and a 52 week low of Rs. 333.25 on 01-Feb-2021.
Last one week high and low of the scrip stood at Rs. 521.05 and Rs. 478.40 respectively. The current market cap of the company is Rs. 26513.31 crore.
The promoters holding in the company stood at 27.27%, while Institutions and Non-Institutions held 28.98% and 43.76% respectively.
Laurus Labs has signed an agreement with MPP (Medicine Patient Pool). The agreement is for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
